Sökning: WFRF:(Carlsson Jessica) >
PD-L1 Expression is...
PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma
-
- Carlsson, Jessica, 1984- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Urology
-
- Sundqvist, Pernilla, 1973- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Urology
-
- Kosuta, Vezira (författare)
- Department of Urology, Faculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden
-
visa fler...
-
- Fält, Anna (författare)
- School of Medical Sciences, Örebro University, Örebro, Sweden,Clinical Epidemiology and Biostatistics
-
- Giunchi, Francesca (författare)
- Molecular Pathology Laboratory, Department of Hematology-Oncology, Addarii Institute of Oncology, University of Bologna, Bologna, Italy
-
- Fiorentino, Michelangelo (författare)
- Molecular Pathology Laboratory, Department of Hematology-Oncology, Addarii Institute of Oncology, University of Bologna, Bologna, Italy
-
- Davidsson, Sabina (författare)
- Department of Urology, Faculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden
-
visa färre...
-
(creator_code:org_t)
- Lippincott Williams & Wilkins, 2020
- 2020
- Engelska.
-
Ingår i: Applied immunohistochemistry & molecular morphology (Print). - : Lippincott Williams & Wilkins. - 1541-2016 .- 1533-4058. ; 28:3, s. 213-220
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Programmed death ligand 1 (PD-L1) is a protein which, when interacting with its receptor programmed death 1, acts as a negative regulator of the antitumor T-cell-mediated immune response. The prognostic value of PD-L1 expression in renal cell carcinoma (RCC) has been controversial. In this study, the prognostic value of PD-L1 expression in RCC was evaluated by analyzing PD-L1 immunoreactivity in tumor cells and tumor-infiltrating immune cells (TIICs) in 346 RCC patients with long-term follow-up. PD-L1 positivity in tumor cells was associated with higher World Health Organization nucleolar grade (P<0.001), recurrence (P=0.011), and death due to RCC (P=0.031). PD-L1 positivity in TIICs was associated with higher nucleolar grade (P<0.001), higher T-stage (P=0.031), higher N-stage (P=0.01), recurrence (P=0.007), and death due to RCC (P=0.001). A significant positive association of time to cancer-specific death with both PD-L1-positive tumor cells and TIICs were also found. The data indicate that RCC patients with PD-L1-positive tumor cells and TIICs are at significant risk for cancer progression and the expression may be used as a complementary prognostic factor in the management of RCC patients.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- programmed death ligand 1
- antitumor immunity
- RCC
- TIICs
- prognostic marker
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas